Updates are available Correction dated 2022-07-18
Click to view Correction: https://doi.org/10.1186/s12014-022-09363-z
-
Authors
Östling, Jörgen
Van Geest, Marleen
Olsson, Henric K.
Dahlen, Sven-Erik
Viklund, Emilia
Gustafsson, Per M.
Mirgorodskaya, Ekaterina
Olin, Anna-Carin http://orcid.org/0000-0001-6674-9020
-
Funding
Funding for this research was provided by:
Stiftelsen för Strategisk Forskning
Hjärt-Lungfonden
The ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype
Forte
- License Information
-
More Information
Article History
Received: 16 November 2021
Accepted: 4 April 2022
First Online: 6 June 2022
Change Date: 2 October 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Change Date: 18 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12014-022-09363-z
Declarations
:
: The study was approved by the ethical committee at Gothenburg University, dnr 390-06. All participants gave their written informed consent to participate.
: All authors have read the last version of the manuscript and approved the manuscript for submission.
: Anna-Carin Olin is reporting competing interests as she is one of the inventors of the PExA method, and boardmember and chairholder of PExA AB. Emilia Viklund is reporting a minor chairhold in PExA AB. Dr Östling reports personal fees from PExA AB during the conduct of the study; and Employed by PExA AB while writing the manuscript but not during the planning and completion of the study.
